|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118307 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-04 09:51:58 |
|
注册时间: Date of Registration: |
2026-02-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
人群健康水平、生活方式、生物标志物与慢性疾病进展风险、康复情况的前瞻性队列研究 |
|
Public title: |
Prospective Cohort Study on Population Health Status, Lifestyle, Biomarkers, and the Risk of Chronic Disease Progression and Rehabilitation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
人群健康水平、生活方式、生物标志物与慢性疾病进展风险、康复情况的前瞻性队列研究 |
|
Scientific title: |
Prospective Cohort Study on Population Health Status, Lifestyle, Biomarkers, and the Risk of Chronic Disease Progression and Rehabilitation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王雪强 |
研究负责人: |
王雪强 |
|
Applicant: |
Wang Xueqiang |
Study leader: |
Wang Xueqiang |
|
申请注册联系人电话: Applicant telephone: |
+86 189 6629 0637 |
研究负责人电话: Study leader's telephone: |
+86 189 6629 0637 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xintong0637@wmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
wangxueqiang@wmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国浙江省温州市龙湾区大道东段1111号 |
研究负责人通讯地址: |
中国浙江省温州市龙湾区大道东段1111号 |
|
Applicant address: |
No.1111, East Section of Longwan Avenue, Wenzhou, Zhejiang, China |
Study leader's address: |
No.1111, East Section of Longwan Avenue, Wenzhou, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
325027 |
研究负责人邮政编码: Study leader's postcode: |
325027 |
|
申请人所在单位: |
温州医科大学附属第二医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Wenzhou Medical University |
||
|
研究负责人所在单位: |
温州医科大学附属第二医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Wenzhou Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审(2025-K-193-02) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
温州医科大学附属第二医院温州医科大学附属育英儿童医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University and Wenzhou Medical University Affiliated Yuying Children's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-26 00:00:00 |
||
|
伦理委员会联系人: |
陈苑 |
||
|
Contact Name of the ethic committee: |
Chen Yuan |
||
|
伦理委员会联系地址: |
中国浙江省温州市龙湾区大道东段1111号 |
||
|
Contact Address of the ethic committee: |
No.1111, East Section of Longwan Avenue, Wenzhou, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 577 8567 6879 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
温州医科大学附属第二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Wenzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国浙江省温州市龙湾区大道东段1111号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1111, East Section of Longwan Avenue, Wenzhou, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划(编号2024YFC3607600) |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key R&D Program (No.2024YFC3607600) |
||||||||||||||||||||||
|
Target disease: |
Chronic disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究旨在通过前瞻性队列设计,系统探讨人群基线健康水平、生活方式特征及生物标志物谱与慢性疾病(如心血管疾病、糖尿病、慢性肾病、肿瘤等)发病风险、疾病进展轨迹及康复预后的关联性。具体目标包括: 1.揭示生活方式(饮食、运动、睡眠、吸烟等)对慢性病发生发展的独立及交互作用; 2.筛选与疾病风险分层和康复预后密切关联的关键生物标志物组合; 3.构建基于多维度数据的慢性病风险预测模型及康复评估体系 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to systematically investigate the associations between baseline health status, lifestyle characteristics, and biomarker profiles in the population with the risk of chronic diseases (e.g., cardiovascular diseases, diabetes, chronic kidney disease, tumors), disease progression trajectories, and rehabilitation outcomes through a prospective cohort design. Specific objectives include: 1. Revealing the independent and interactive effects of lifestyle factors (diet, exercise, sleep, smoking, etc.) on the onset and progression of chronic diseases; 2. Screening key biomarker combinations closely associated with disease risk stratification and rehabilitation outcomes; 3. Establishing a multidimensional data-based chronic disease risk prediction model and rehabilitation assessment system. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
入选标准: 1.年龄≥18周岁,认知功能正常,能独立完成问卷及检测; 2.自愿签署知情同意书,承诺完成长期随访; 3.基线无目标慢性疾病(如心梗、脑卒中、晚期肾病、恶性肿瘤等)。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria: 1.Age >=18 years, normal cognitive function, capable of independently completing questionnaires and examinations; 2.Voluntary signing of informed consent, commitment to long-term follow-up; 3.No baseline target chronic diseases (e.g., myocardial infarction, stroke, advanced renal disease, malignant tumors, etc.). |
||||||||||||||||||||||
|
排除标准: |
排除标准: 1.拒绝参与研究或无法配合调查(如精神障碍、严重视听障碍); 2.基线已确诊终末期疾病(如晚期肿瘤、尿毒症)或预期生存期<5年。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: 1.Refusal to participate in the study or inability to cooperate with the investigation (e.g., mental disorders, severe visual or auditory impairments); 2.Confirmed end-stage disease at baseline (e.g., advanced tumors, uremia) or expected survival time <5 years. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-01 00:00:00至 To 2028-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-03-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
在设盲方面实施部分盲法,具体包括:由多学科专家组成的终点事件判定委员会在评估疾病进展时不知晓受试者暴露状态;实验室检测人员对生物标志物分析时保持盲态;虽然受试者知晓自身生活方式无法设盲,但通过标准化问卷和客观检测指标最大限度减少偏倚。 |
|
Blinding: |
Partial blinding was implemented in the study design, specifically including: a multidisciplinary expert committee for endpoint adjudication was unaware of the subjects' exposure status when assessing disease progression; laboratory personnel maintained blinding during biomarker analysis; although subjects were aware of their lifestyle and thus could not be blinded, standardized questionnaires and objective testing metrics were used to minimize bias. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |